The Latest
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Including Contineum’s IPO, biotechs have now raised about $1.43 billion in new stock offerings this year, nearly quadrupling last year’s total by this point.
Updated an hour ago -
Permission granted by PHC Corporation of North America
Sponsored by PHC Corporation of North America (PHCNA)Keeping cleanrooms clean: Choosing the right laboratory equipment is key
Because live cell and tissue products are sensitive to contamination from microorganisms, viral particles or other impurities, research and manufacturing involving these materials needs to be conducted in a cleanroom environment.
-
Courtesy of Vertex Pharmaceuticals
Vertex begins bid for US approval of non-opioid painkiller
The biotech has begun a rolling submission of a closely watched drug that’s important to its future, but faces questions of sales potential.
-
Brad Barket via Getty Images
23andMe CEO plans to take company private
Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.
-
Scott Olson via Getty Images
Obesity drugsLilly obesity drug shows benefit in sleep disorder study, pointing to new use
Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.
-
noparrit via Getty Images
Sage’s cognition drug fails in Parkinson’s study
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is on the upswing. Track the latest deals here.
Vertex’s proposed buyout of Alpine Immune Sciences is the largest biotech acquisition to be announced so far this year.
Updated April 10, 2024 -
Courtesy of Teva Pharmaceutical
Stelara biosimilar from Alvotech, Teva approved by FDA
The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.
-
Permission granted by Canaan
Canaan hires Pfizer executive, reels in $100M for biotech investing
The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.
-
Mario Tama via Getty Images
J&J sees mixed performance from new multiple myeloma drugs
Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."
-
Eoneren via Getty Images
Intra-Cellular builds case for depression drug with late-stage trial win
Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.
-
Dr_Microbe via Getty Images
Cullinan changes name, pivots to autoimmune disease
The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.
-
Regeneron commits $500M to new venture capital fund
While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.
-
Permission granted by Neumora Therapeutics
Neumora’s schizophrenia drug hit with clinical hold
Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.
-
iStock via Getty Images
Roche reports survival data for new dual-acting lymphoma drug
The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.
-
Image courtesy of Ultragenyx.
Ultragenyx says Angelman therapy is working, but safety questions remain
Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.
-
Spencer Platt via Getty Images
Biotech IPOs bounced back in first quarter, but backlog remains
Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show.
-
Mario Tama via Getty Images
European regulator concludes no suicide link to obesity drugs
The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.
-
Nemes Laszlo via Getty Images
Roche, Adaptimmune part ways on cell therapy research
The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.
-
Regeneron
US sues Regeneron, alleging false price reporting on Eylea
The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.
-
Permission granted by Vertex Pharmaceuticals
Vertex to buy kidney disease drugmaker Alpine for $4.9B
A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.
Updated April 11, 2024 -
luismmolina via Getty Images
Emerging biotechCentury buys a startup, raises funding in cell therapy expansion
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
-
PeopleImages via Getty Images
J&J, Rallybio partner on drug development for rare fetal condition
The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.
-
Novartis
Novartis pauses enrollment in some Kisqali trials to fix manufacturing
The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.
-
Jeenah Moon via Getty Images
RSV vaccinesPfizer, with new study results, seeks to bring RSV shot to adults aged 18-59
The company plans to submit the trial data to regulators in a bid to win approval of its vaccine Abrysvo in adults as young as 18 years old.
-
whitehoune via Getty Images
Emerging biotechPureTech launches Seaport, hoping to create Karuna 2.0
The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.
